All posts by medical

Medicare drops AUC requirement for advanced imaging, ASNC celebrates – Cardiovascular Business

Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: dfornell@innovatehealthcare.com

Originally posted here:

Medicare drops AUC requirement for advanced imaging, ASNC celebrates - Cardiovascular Business

Yale Faculty Present Groundbreaking Clinical Research at the 2024 American College of Cardiology Scientific Sessions – Yale School of Medicine

The American College of Cardiology (ACC) is holding its annual Scientific Meeting on April 6-8, 2024, where Yale faculty and trainees will present their latest clinical research.

Yales commitment to research is on full display at this years American College of Cardiology conference, where dozens of our faculty and trainees will share their contributions to science with our colleagues across the world, said Eric J. Velazquez, MD, Robert W. Berliner Professor of Medicine and chief of Yale Cardiovascular Medicine. Im extremely proud to lead a group of doctors and scientists who come to work each and every day thinking about how to advance the field of cardiovascular medicine all with the goal of providing patients with the best possible care.

Key presentations featuring Yale faculty and trainees include:

9:30 - 11:00 a.m. Session 1007: Outcome Prediction by Multimodality Imaging in Chronic CAD Moderated Poster Theater 07

9:30 - 11:00 a.m. Session 1008: Recognizing and Eliminated Disparities in CVD Moderated Poster Theater 08

9:45 - 10:30 a.m. Session 1201: Critical Care Cardiology 01 Hall B4-5

9:45 - 10:30 a.m. Session 1202: Innovation, Digital Health, and Technology 01 Hall B4-5

9:45 - 10:30 a.m. Session 1203: Vascular Medicine: Clinical Science 01 Hall B4-5

10:45 - 11:30 a.m. Session 1221: Complex Clinical Cases: FIT Valvular Heart Disease 02 Hall B4-5

10:45 - 11:30 a.m. Session 1232: Multimodality Imaging: Clinical Science 02 Hall B4-5

11:45 a.m. - 12:30 p.m. Session 1242: Spotlight on Special Topics: Cardio-OB 03 Hall B4-5

12:45 - 1:30 p.m. Session 1261: Innovation, Digital Health, and Technology 04 Hall B4-5

12:45 - 1:30 p.m. Session 1263: Vascular Medicine: Basic and Translational Science 04 Hall B4-5

1:30 - 3:00 p.m. Session 1032: Refining the Art of Implementation Science Moderated Poster Theater 08

1:45 - 2:30 p.m. Session 1282: Global Cardiovascular Health 05 Hall B4-5

1:45 - 2:30 p.m. Session 1283: Pulmonary Vascular Disease: Clinical and Population Science 05 Hall B4-5

1:45 - 2:30 p.m. Session 1288: Interventional and Structural: Endovascular Interventions 05 Hall B4-5

1:45 - 2:30 p.m. Session 1289: Interventional and Structural: Aortic Valve Interventions 05 Hall B4-5

2:45 - 3:30 p.m. Session 1305: Heart Failure and Cardiomyopathies: Clinical Science 06 Hall B4-5

2:45 - 3:30 p.m. Session 1307: Ischemic Heart Disease: Clinical Science 06 Hall B4-5

3:30 - 5:00 p.m. Session 1038: Back to the Future: Application of AI and ML in Heart Failure Moderated Poster Theater 02

3:30 - 5:00 p.m. Session 1045: Simulations and AI-Based Predictions Enhancing CV Care Moderated Poster Theater 09

3:45 - 4:30 p.m. Session 1321: Cardio-oncology 07 Hall B4-5

3:45 - 4:30 p.m. Session 1322: Vascular Medicine: Venous and Thromboembolic Disease 07 Hall B4-5

4:15 - 5:30 p.m. Session 632: Older and Wiser: Improving Health Across the Lifespan For Older Adults With Ischemic Heart Disease B401

8:00 - 9:15 a.m. Session 504: April Adventure: Top Interventional Trials of 2023 Thomas B. Murphy Ballroom 2

8:00 - 9:15 a.m. Session 1050: #GDMT Works: From Heart Failure to Heart Success Moderated Poster Theater 02

9:00 - 10:30 a.m. Session 1052: Peripheral Vascular Disease Moderated Poster Theater 04

9:15 - 10:00 a.m. Session 1340: Complex Clinical Cases: FIT Heart Failure 08 Hall B4-5

9:15 - 10:00 a.m. Session 1342: Vascular Medicine: Special Populations08 Hall B4-5

9:15 - 10:00 a.m. Session 1343: Heart Failure and Cardiomyopathies: Pharmacology 08 Hall B4-5

9:15 - 10:00 a.m. Session 1353: Prevention and Health Promotion: Diabetes and Cardiometabolic Disease 08 Hall B4-5

9:15 - 10:15 a.m. Session 2007: Heart Tank For the Cardiovascular Investigator: The Susan Smyth Memorial Tournament of Champions Engage Stage

9:45 - 11:00 a.m. Session 712: Joint Symposium of the American Heart Association and the American College of Cardiology B206

9:45 - 11:00 a.m. Session 505: April Adventure: The Great ECG Challenge Thomas B. Murphy Ballroom 2

9:45 - 11:00 a.m. Session 909: Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review B207

10:15 - 11:00 a.m. Session 1362: Training and Lifelong Learning 09 Hall B4-5

10:15 - 11:00 a.m. Session 1366: Ischemic Heart Disease: Clinical Science 09 Hall B4-5

10:15 - 11:00 a.m. Session 1371: Electrophysiology: Population Science 09 Hall B4-5

10:15 - 11:00 a.m. Session 1372: Prevention and Health Promotion: Diabetes and Cardiometabolic Disease 09 Hall B4-5

11:00 a.m. - 12:30 p.m. Session 1062: Neph Bomb: Decongestion in Heart Failure Moderated Poster Theater 02

11:00 a.m. - 12:30 p.m. Session 1064: Impact of Age on Interventional Cardiology Care Moderated Poster Theater 04

11:00 a.m. - 12:30 p.m. Session 1065: Vascular Vistas: Tailored Research For Special Populations Moderated Poster Theater 05

11:15 a.m. - 12:00 p.m. Session 1382: Critical Care Cardiology 10 Hall B4-5

11:15 a.m. - 12:00 p.m. Session 1384: Heart Failure and Cardiomyopathies: Population Science 10 Hall B4-5

11:15 a.m. - 12:00 p.m. Session 1385: Ischemic Heart Disease: Pharmacology 10 Hall B4-5

11:15 a.m. - 12:00 p.m. Session 1393: Prevention and Health Promotion: Population Science 10 Hall B4-5

12:15 - 1:00 p.m. Session 1401: Critical Care Cardiology 11 Hall B4-5

12:15 - 1:00 p.m. Session 1403: Vascular Medicine: Clinical Science 11 Hall B4-5

12:15 - 1:00 p.m. Session 1414: Prevention and Health Promotion: Lipids 11 Hall B4-5

1:00 - 2:30 p.m. Session 1075: Bulking Up Advances in Hypertrophic Cardiomyopathy Moderated Poster Theater 03

2:15 - 3:00 p.m. Session 1453: Prevention and Health Promotion: Diabetes and Cardiometabolic Disease 13 Hall B4-5

2:15 - 3:00 p.m. Session 1454: Prevention and Health Promotion: Lipids 13 Hall B4-5

3:15 - 4:00 p.m. Session 1461: Critical Care Cardiology 14 Hall B4-5

4:30 - 5:45 p.m. Session 709: Treating Arrhythmias in Athletes: When, Who and How? B312

8:30 - 9:45 a.m. Session 913: Highlighted Original Research: Interventional and Structural and the Year in Review B405

8:30 - 9:45 a.m. Session 914: Highlighted Original Research: Multimodality Imaging and the Year in Review B213

9:00 - 10:30 a.m. Session 1099: New Analyses From Heart Failure Clinical Trials Moderated Poster Theater 03

9:00 - 10:30 a.m. Session 1102: Not Just a Number: Ischemic Heart Disease in Older Populations Moderated Poster Theater 06

9:00 - 10:30 a.m. Session 1103: Quantitative Markers of Clinical Risk From Multimodality Imaging Moderated Poster Theater 07

9:00 - 10:30 a.m. Session 1104: Sex, Gender, Hormones, and the Heart Moderated Poster Theater 08

9:45 - 10:30 a.m. Session 1482: Vascular Medicine: Special Populations 15 Hall B4-5

9:45 - 10:30 a.m. Session 1487: Ischemic Heart Disease: Special Populations 15 Hall B4-5

9:45 - 10:30 a.m. Session 1489: Multimodality Imaging: MR 15 Hall B4-5

9:45 - 10:30 a.m. Session 1492: Prevention and Health Promotion: Lipids 15 Hall B4-5

10:45 - 11:30 a.m. Session 1501: Complex Clinical Cases: FIT Ischemic Heart Disease and Heart Failure 16 Hall B4-5

10:45 - 11:30 a.m. Session 1504: Heart Failure and Cardiomyopathies: Clinical Science 16 Hall B4-5

10:45 - 11:30 a.m. Session 1505: Ischemic Heart Disease: Population Science 16 Hall B4-5

10:45 - 11:30 a.m. Session 1508: Interventional and Structural: Coronary Interventions 16 Hall B4-5

11:00 a.m. - 12:15 p.m. Session 734: Finding Balance: Wellness in the CHD Clinician B308

11:00 a.m. - 12:30 p.m. Session 1114: Trends in Ischemic Heart Disease Moderated Poster Theater 06

11:00 a.m. - 12:30 p.m. Session 1115: Imaging Science on the Verge of Clinical Translation Moderated Poster Theater 07

11:45 a.m. - 12:30 p.m. Session 1520: Complex Clinical Cases: MD/PhD 17 Hall B4-5

11:45 a.m. - 12:30 p.m. Session 1523: Vascular Medicine: Clinical Science 17 Hall B4-5

12:45 - 1:30 p.m. Session 1546: Ischemic Heart Disease: Special Populations 18 Hall B4-5

12:45 - 2:00 p.m. Session 742: 2024 Eugene Braunwald Keynote Thomas B. Murphy Ballroom 4

2:30 - 3:45 p.m. Session 759: Step-by-Step Management of Patients With AFIB and LAA Occlusion in 2024 B405

View original post here:

Yale Faculty Present Groundbreaking Clinical Research at the 2024 American College of Cardiology Scientific Sessions - Yale School of Medicine

Getting Too Little Sleep Linked to High Blood Pressure – Diagnostic and Interventional Cardiology

April 1, 2024 Sleeping fewer than seven hours is associated with a higher risk of developing high blood pressure over time, according to a study to be presented during the April 6-8American College of Cardiologys Annual Scientific Session & Expo, ACC.24.

While the association between sleep patterns and high blood pressure has been reported, evidence about the nature of this relationship has been inconsistent, according to researchers. The current analysis pools data from 16 studies conducted between January 2000 and May 2023, evaluating hypertension incidence in 1,044,035 people from six countries who did not have a prior history of high blood pressure over a median follow-up of five years (follow-up ranged from 2.4 to 18 years). Short sleep duration was significantly associated with a higher risk of developing hypertension after adjusting for demographic and cardiovascular risk factors, including age, sex, education, BMI, blood pressure, smoking status etc. Furthermore, the association was found to be even stronger for those getting less than five hours of sleep.

Based on the most updated data, the less you sleepthat is less than seven hours a daythe more likely you will develop high blood pressure in the future, said Kaveh Hosseini, MD, assistant professor of cardiology at the Tehran Heart Center in Iran and principal investigator of the study. In a news release summarizing the study, Hosseini added, We saw a trend between longer sleep durations and a greater occurrence of high blood pressure, but it was not statistically significant. Getting seven to eight hours of sleep, as is recommended by sleep experts, may be the best for your heart too.

The study found that sleeping less than seven hours was associated with a 7% increased risk of developing high blood pressure, which spiked to 11% when reported sleep duration was less than five hours. By comparison, diabetes and smoking are known to heighten ones risk of hypertension by at least 20%, Hosseini said.

While the study did not look at why this might be the case, Hosseini said that disrupted sleep could be to blame. For example, he said lifestyle habits or comorbid conditions such as overeating, alcohol use, nightshift work, certain medication use, anxiety, depression, sleep apnea or other sleep disorders may be factors.

Researchers were surprised there were no age-based differences in the association between sleep duration and hypertension given that sleep patterns tend to shift with age. The age of the participants ranged from 35.4 years to 60.9 years and more than half (61%) were female. When compared with men, females who reported less than seven hours of sleep had a 7% greater risk of developing high blood pressure.

Getting too little sleep appears to be riskier in females, Hosseini said. The difference is statistically significant, though we are not sure its clinically significant and should be further studied. What we do see is that lack of good sleep patterns may increase the risk of high blood pressure, which we know can set the stage for heart disease and stroke.

It's important for people to talk with their health care team about their sleep patterns, especially if they have disrupted sleep that might be due to obstructive sleep apnea. Sleep apnea has been tied to higher rates of high blood pressure, stroke and coronary artery disease.

This study has several limitations, including that sleep duration was based on self-reported questionnaires, so changes in sleep duration over the follow-up period were not assessed. Moreover, there were variations in how short sleep duration was defined between the studies (fewer than five or six hours).

Further research is required to evaluate the association between sleep duration and high blood pressure using more accurate methods like polysomnography, a method for evaluating sleep quality more precisely, Hosseini said. Moreover, the variations in reference sleep duration underline the need for standardized definition in sleep research to enhance the comparability and generalizability of findings across diverse studies.

Aayushi Sood, MD, lead author and medical resident at The Wright Center for Graduate Medical Education, will present the study, Sleep Duration and Hypertension Incidence: Systematic Review and Meta-Analysis, on Sunday, April 7 at 9:15 a.m. / 13:15 UTC in Hall B4-5.

ACC.24 will take place April 6-8, 2024, in Atlanta, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention.

For more information: http://www.acc.org

Find more ACC24 conference coverage here

See original here:

Getting Too Little Sleep Linked to High Blood Pressure - Diagnostic and Interventional Cardiology

What’s Going to Be Hot at ACC 2024 – TCTMD

Later this week, the American College of Cardiology (ACC) 2024 Scientific Session celebrates its 75th anniversary by heading back to Atlanta for the first time since 2010, with the plans to return in 2021 dashed by the COVID-19 pandemic. In this years lineup are some eagerly awaited cardiovascular trials in the drug and device space, but also some less traditional approaches assessing game-based and financial incentives, spirituality, and unique population approaches.

According to Douglas Drachman, MD (Massachusetts General Hospital, Boston), the scientific sessions chair, 2024 will be a blockbuster of a year for the meeting, which received 1,100 more abstracts than last year and the most its received in two decades, with submissions coming from 79 countries worldwide. There was truly global input into this meeting and certainly we hope for global impact, Drachman told a media telebriefing last week.

Late-Breaking Lineup

There will be a total of five late-breaking clinical trial (LBCT) sessions spread over the 3-day meeting. LBCT I, on Saturday, showcases just three trials: RELIEVE-HF, EMPACT-MI, and AEGIS II. This last trial, we already know from top-line results, came up empty-handed and in doing so delivered what might be a mortal blow to the HDL-raising hypothesis.

RELIEVE-HF, by contrast, is exploring newer terrain. This the second-ever randomized trial of an atrial shunt to relieve pulmonary pressure in heart failure: early positive signals reported 2 years ago raised some hopes that this trial might yield better results than REDUCE LAP-HF II, where a different atrial shunt device proved no better than a sham procedure for relieving pulmonary wedge pressures.

From my standpoint, Im hopeful that this allows us to advance the care of people who are still refractory, said Katie Berlacher, MD (University of Pittsburgh, PA), who serves as the meetings vice chair and co-moderated the briefing. There are many patients who we have, both with reduced and preserved ejection fraction, that despite many of our really good medical therapies, they either can't be on more because they don't tolerate more, or they're on the most and they are still having heart failure [symptoms]. So I'm incredibly curious about a structural change to the heart that then treats this.

Rounding out LBCT I is EMPACT-MI, testing empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) prescription immediately after acute MI to reduce subsequent MACE over usual care. Here, too, ACC attendees will be thinking of a predecessor: DAPA-MI, presented at last years American Heart Association meeting, which tested dapagliflozin (Farxiga; AstraZeneca) in acute MI and also came up empty-handed. Notably, however, DAPA-MI specifical excluded patients with diabetes, whereas EMPACT-MI did not.

Sunday morning features two late-breaking sessions. LBCT II, at 8 AM, features a mix of lipid-lowering trials, the phase II KARDIA-2 hypertension trial testing zilebesiran (Alnylam), and a novel approach using gamification, financial incentives, or both to induce patients at risk of adverse CV events to be more physically active.

LBCT III, at 11 AM, is dominated by MI and ACS trials, the most hotly anticipated being DANGER-SHOCK testing the Impella percutaneous transvalvular micro-axial flow pump (Abiomed) in patients presenting with acute MI complicated by cardiogenic shock. As previously reported by TCTMD, this trial has faced uphill battles enrolling and randomizing the sickest of patients, leading to a steady stream of imperfect, observational studies to try to fill the knowledge gap.

Other LBCT III trials also will likely make headlines. TACT2 is revisiting the enticing idea that chelation might help post-MI in patients with diabetes. REDUCE-AMI is tackling the long-running question of whether long-term beta-blockers are helpful after MI in patients with preserved ejection fraction, particularly in the current era of guideline-directed medical therapy. Lastly, the ULTIMATE DAPT trial is the latest trial to try to cut down on post-PCI antiplatelet therapy regimens, this time with a strategy of just 1-month of ticagrelor monotherapy after ACS.

A lone structural heart disease trial appears in that session: the SMART trial is comparing a balloon-expandable and a self-expanding TAVI valve in patients with small aortic annuli.

Cardiomyopathies get the spotlight Monday morning. LBCT IV features two new agents and one old, in this space. ARISE-HF tested a selective aldose reductase inhibitor (at-001; Applied Therapeutics) for the treatment of diabetic cardiomyopathy. IMPROVE-HCM examined ninerafaxstat (Imbria Pharmaceuticals), a novel cardiac mitotrope, in patients with symptomatic nonobstructive hypertrophic cardiomyopathy. PROACT, however, features an old drug, the ACE inhibitor enalapril, for the possibility of preventing anthracycline-induced cardiotoxicity in breast cancer and lymphoma patients. The last two trials in LBCT IV are a study of tranexamic acid to prevent seizures after cardiac surgery and TACTiC, testing a technology-assisted means of administering nonprescription rosuvastatin.

The last late-breaking session of ACC 2024 delivers an interventional cardiology wallop. LBCT V includes ORBITA-COSMIC, a placebo-procedure-controlled trial of a coronary sinus reducer for refractory angina; DEDICATE-DZHK6, pitting surgery against TAVI in low- and intermediate-risk patients; the Target BP I trial of renal denervation, an IVUS versus angiography to guide drug-coated balloon therapy in femoropopliteal artery disease; and preventive PCI versus medical therapy in patients with unstable coronary plaques. This last, said Drachman during the ACC press briefing, is sort of the Holy Grail of cardiologypreventing a future heart attack[and] I hope this trial will give more insights.

More Science

Each of the late breakers get a second look in deep-dive sessions scheduled later in the day each day. There are also three featured clinical research sessions, one per day, showcasing updates from recent trials or novel registry analyses.

Some outside-the-box studies have been grouped under the umbrella of Clinical and Investigative Horizons on Saturday and include a registry-based, decentralized trial addressing ways of providing more equitable cardiovascular care, a study of CVD risk factors among National Football League players and families, an implementation science study aimed at increasing heart failure therapies among members of the Navajo Nation, and a study gauging the effects of spirituality on blood pressure.

It's not all trials and science, of course, as the meetings CV Team Lead Kimberly Guibone, DNP (Beth Israel Deaconess Medical Center, Boston, MA), explained to the media. There are dedicated sessions focused on business of medicine concerns for healthcare professionals, 11 game show-style sessions complete with quizzes, lights, and buzzers, andby popular demandthe puppies are back for stressed out conference attendees to get their hands on.

For more on whats to come at ACC 2024, check out the latest Rox Heart Radio. The TCTMD team will be on-site in Atlanta. Please reach out with tips, complaints, and comments: we hope to see you there.

Read more:

What's Going to Be Hot at ACC 2024 - TCTMD

E-cigarette use linked to increased risk of heart failure, large study finds – News-Medical.Net

People who use e-cigarettes are significantly more likely to develop heart failure compared with those who have never used them, according to one of the largest prospective studies to date investigating possible links between vaping and heart failure. The findings are being presented at the American College of Cardiology's Annual Scientific Session.

Heart failure is a condition affecting more than 6 million U.S. adults in which the heart becomes too stiff or too weak to pump blood as effectively as it should. It can often lead to debilitating symptoms and frequent hospitalizations as people age. Electronic nicotine products, which include e-cigarettes, vape pens, hookah pens, personal vaporizers and mods, e-cigars, e-pipes and e-hookahs, deliver nicotine in aerosol form without combustion. Since they were first introduced in the U.S. in the late 2000s, electronic nicotine products have often been portrayed as a safer alternative to smoking, but a growing body of research has led to increased concern about potential negative health effects.

More and more studies are linking e-cigarettes to harmful effects and finding that it might not be as safe as previously thought. The difference we saw was substantial. It's worth considering the consequences to your health, especially with regard to heart health."

Yakubu Bene-Alhasan, MD, a resident physician at MedStar Health in Baltimore and the study's lead author

For the study, researchers used data from surveys and electronic health records in All of Us, a large national study of U.S. adults run by the National Institutes of Health, to analyze associations between e-cigarette use and new diagnoses of heart failure in 175,667 study participants (an average age of 52 years and 60.5% female). Of this sample, 3,242 participants developed heart failure within a median follow-up time of 45 months.

The results showed that people who used e-cigarettes at any point were 19% more likely to develop heart failure compared with people who had never used e-cigarettes. In calculating this difference, researchers accounted for a variety of demographic and socioeconomic factors, other heart disease risk factors and participants' past and current use of other substances, including alcohol and tobacco products. The researchers also found no evidence that participants' age, sex or smoking status modified the relationship between e-cigarettes and heart failure.

Breaking the data down by type of heart failure, the increased risk associated with e-cigarette use was statistically significant for heart failure with preserved ejection fraction (HFpEF)-;in which the heart muscle becomes stiff and does not properly fill with blood between contractions. However, this association was not significant for heart failure with reduced ejection fraction (HFrEF)-;in which the heart muscle becomes weak and the left ventricle does not squeeze as hard as it should during contractions. Rates of HFpEF have risen in recent decades, which has led to an increased focus on determining risk factors and improving treatment options for this type of heart failure.

The findings align with previous studies conducted in animals, which signaled e-cigarette use can affect the heart in ways that are relevant to the heart changes involved in heart failure. Other studies in humans have also shown links between e-cigarette use and some risk factors associated with developing heart failure. However, previous studies attempting to assess the direct connection between e-cigarette use and heart failure have been inconclusive, which Bene-Alhasan said is due to the inherent limitations of the cross-sectional study designs, smaller sample sizes and the smaller number of heart failure events seen in previous research.

Researchers said the new study findings point to a need for additional investigations of the potential impacts of vaping on heart health, especially considering the prevalence of e-cigarette use among younger people. Surveys indicate that about 5% to 10% of U.S. teens and adults use e-cigarettes. In 2018, the U.S. Surgeon General called youth e-cigarette use an epidemic and warned about the health risks associated with nicotine addiction.

"I think this research is long overdue, especially considering how much e-cigarettes have gained traction," Bene-Alhasan said. "We don't want to wait too long to find out eventually that it might be harmful, and by that time a lot of harm might already have been done. With more research, we will get to uncover a lot more about the potential health consequences and improve the information out to the public."

Bene-Alhasan also said e-cigarettes are not recommended as a tool to quit smoking, since many people may continue vaping long after they quit smoking. The U.S. Centers for Disease Control and Prevention recommends a combination of counseling and medications as the best strategy for quitting smoking.

Researchers said that the study's prospective observational design allows them to infer, but not conclusively determine, a causal relationship between e-cigarette use and heart failure. However, with its large sample size and detailed data on substance use and health information, Bene-Alhasan said the study is one of the most comprehensive studies to assess this relationship to date.

More here:

E-cigarette use linked to increased risk of heart failure, large study finds - News-Medical.Net

Osso VR and ACC to Develop Cardiac Procedure Training with VR – HIT Consultant

What You Should Know:

Osso VR, the leader in immersive procedural training, announces a groundbreaking collaboration with the American College of Cardiology (ACC) to develop a state-of-the-art training curriculum for left atrial appendage occlusion (LAAO) procedures.

The strategic partnership marks a significant leap forward in the field of medical education, leveraging virtual reality (VR) technology to enhance interventional cardiologists training.

The Focus: Left Atrial Appendage Occlusion (LAAO)

The co-developed curriculum focuses on LAAO, a critical procedure that reduces stroke risk in patients with atrial fibrillation. Mastering LAAO requires a diverse skillset, including Transesophageal Echocardiography (TEE). Osso VRs immersive platform addresses this by providing:

ACCs goal is to improve access to high-quality cardiovascular care. We are thrilled to collaborate with Osso VR to augment traditional interventional training for some of the more complex and cutting-edge procedures in our field, said Ami Bhatt, MD, FACC, ACC Chief Innovation Officer. This collaboration is the first step in a broader effort to increase access to consistent interventional cardiovascular care in the U.S. and globally.

Read more:

Osso VR and ACC to Develop Cardiac Procedure Training with VR - HIT Consultant

Pygmy Slow Lorises Are Born at Smithsonian’s National Zoo and Conservation Biology Institute – Smithsonian’s National Zoo and Conservation Biology…

For the first time, the Smithsonians National Zoo and Conservation Biology Institute (NZCBI) is celebrating the birth of two pygmy slow lorises, an endangered species. Small Mammal House keepers reported for duty the morning of March 21 and observed that 3-year-old mother Naga had given birth overnight and was caring for two infants. She and the babies 2-year-old father, Pabu, received a recommendation to breed from the Association of Zoos and Aquariums Species Survival Plan (SSP). These babies are the first offspring for both parents. Keepers have observed Naga carrying, grooming and nursing the babies, which appear to be healthy and strong. Animal care staff will determine the babies sexes at their first vet exam, which will take place in a few months. The family is on view at the Small Mammal House, and keepers say the babies are most active in the late morning and early afternoon.

Naga and Pabu arrived at NZCBI in August 2022 from the Brookfield Zoo in Illinois and Little Rock Zoo in Arkansas, respectively.SSP scientists determine which animals to breed by considering their genetic makeup, health and temperament, among other factors. According to keepers, Nagas personality is calm and sweet, though she tends to spook easily. She takes her time when exploring her exhibit and rests often. Pabu, on the other hand, seems to be more high energy. He is inquisitive and always the first to approach keepers and participate in training sessions and feedings. Although pygmy slow lorises reach sexual maturity around 9 months of age for females and 1.5 years of age for males, often they do not successfully reproduce until 2 to 3 years of age. Naga and Pabus howdy introductions took place in September 2023about a year after they arrivedand the pair bred soon after meeting. This species gestation is about six months.

Pygmy slow loris mothers are the primary caregivers of their offspring. In the wild and in zoos, fathers occasionally interact with offspring, depending on their personality and past experience with babies. Pabu has proved to be an attentive and patient father. Keepers have observed him grooming his family and caring for the babies when Naga leaves the nest to forage for food. Visitors may see the babies clinging to Naga as she moves around the exhibit.On occasion, she will leave the babies in their nest or on a branch while she eats or explores. Keepers look forward to watching the babies independently explore their exhibit and play with enrichment items.

Slow lorises are the only known venomous primates. They produce a venom in their brachial glands in their upper arm. Combined with enzymes in their saliva, these primates can produce a painful bite, allergic reaction and a slow-healing wound. Wild slow lorises do not use it against predators because the venom is not fast-acting. Instead, the venom is used in territorial disputes with other slow lorises. They also groom themselves with the venom to ward off parasites and warn predators to stay away.

Native to Cambodia, Lao Peoples Democratic Republic and Vietnam, pygmy slow lorises live in mixed deciduous and evergreen forests. The greatest threats facing this species are deforestation and the illegal pet trade. Much of their habitat has been cleared for the logging industry; they spend the majority of their time from 10 to 40 feet up in the forest canopy.TheInternational Union for Conservation of Natureconsiders pygmy slow lorisesendangered.

# # #

Photo caption: The Smithsonians National Zoo and Conservation Biology Institute welcomed two pygmy slow lorises babies March 21 to mother Naga and father Pabu in the Small Mammal House. Photo credit: Kara Ingraham, Smithsonians National Zoo and Conservation Biology Institute

Read this article:

Pygmy Slow Lorises Are Born at Smithsonian's National Zoo and Conservation Biology Institute - Smithsonian's National Zoo and Conservation Biology...

Inside the new Seattle Hub for Synthetic Biology, which uses DNA to ‘record biology over time’ – GeekWire

Scientist Sundarshan Pinglay shows off a liquid handling instrument that automatically dispenses reagents, at the Seattle Hub for Synthetic Biology. (GeekWire Photo / Charlotte Schubert)

Researchers opened the doors Monday to the new Seattle Hub for Synthetic Biology, a collaboration between theAllen Institute, theChan Zuckerberg Initiativeand theUniversity of Washington.

The hub combines academic creativity with startup-style industrial execution, said Jesse Gray, senior director of scientific operations and strategy, who was previously head of discovery at gene editing startup Ascidian Therapeutics.

The hubs first main goal is to build a biological recorder mouse, enabling researchers to track biological actions such as cell divisions and molecular signaling in a live mouse across time.

Mondays tour took place at the hubs labs at Dexter Yard, a life sciences development in the South Lake Union neighborhood across from the Allen Institute, which is contributing $35 million to the hub over the next five years.

The Chan Zuckerberg Initiative is providing the same amount, and the UW is a source of foundational technology for the new hub.

The initiative leverages DNA-based technology developed in the lab of the hubs lead scientific director Jay Shendure, a UW professor of genome sciences. During the tour, he called the approach a symbolic language for longitudinally recording biology over time.

The method involves generating DNA barcodes for each cell that reflect biological activity. Scientists place a DNA tape inside a founder or stem cell. The DNA tape is edited through generations of cell division, with each edit occurring in sequential order along the tape generating a readout of the timing of cellular events.

Shendure and his colleagues introduced this DNA typewriter technique in a 2022 study published in Nature. There, they used the method to reconstruct a cell lineage tree, tracing how a single cell multiplied into thousands of cells. More recently, his lab adapted the technique to record the long-term activity of cell signals.

Ultimately, the researchers think the methods can be used to trace an even broader variety of cellular states and actions, such as metabolic status, cell-cell contact, and neuronal signaling.

The approach is foundational technology said Stephen Quake, head of science at the Chan Zuckerberg Initiative, during a fireside chat at the Allen Institute. New drugs and treatment should ultimately result from the research, he said.

Potential applications include assessing the actions of therapeutic cells and improving their design. Another application might be to track body-wide how a mouse responds over time to specific drugs or other perturbations.

Marion Pepper, professor and chair of Immunology at the UW, is excited to explore potential uses in immunotherapy.

Having these types of tools and technological developments applied to immune cells will revolutionize how we treat disease, said Pepper, who co-directs the hub with UW associate professor of genome sciences Cole Trapnell. Were going to learn so much about these cells that weve never been able to visualize or understand, added Pepper.

The Seattle Hub for Synthetic Biology, first announced in December, now has 15 staff members and plans to hire up to a dozen more by the end of next year, and around 50 within five years.

Shendure sees an opportunity to snap up talent with industry experience and the ability to spot commercial opportunities. At the same time, both the Allen Institute and the Chan Zuckerberg Initiative have a commitment to open science a culture that has also eased their collaboration, said hub leaders.

The Seattle Hub for Synthetic Biology currently occupies 3,600 square feet in Dexter Yard, and will expand to 12,000 square feet in 2025. During the tour, visitors were introduced to four research stations.

Read more:

Inside the new Seattle Hub for Synthetic Biology, which uses DNA to 'record biology over time' - GeekWire

VespAI: a deep learning-based system for the detection of invasive hornets | Communications Biology – Nature.com

Bait station

Bait stations consisted of a Dragon Touch Vision 1 1080p camera, suspended at a height of 210mm above a featureless detection board, shielded by an opaque baffle (Fig.4). This setup minimised background and lighting variability, thus simplifying the computational complexity of hornet detection, while ensuring that only hornets and other insects visiting the station were captured in videos. A sponge cloth impregnated with commercial vespid attractantVespaCatch (Vto-pharma) or Trappit (Agrisense)was placed in a 90mm diameter Petri dish at the centre of the bait station, thus attracting hornets to land directly beneath the camera. We used these bait stations to collect and extract an extensive training dataset, comprising images of V. velutina, V. crabro, and other insects across locations in Jersey, Portugal, France, and the UK.

To ensure dataset fidelity, resultant images of both V. velutina and V. crabro were visually identified via expert assessment of colouration, abdominal markings, and morphology. Additionally, the identity of each hornet species was confirmed through utilisation of the appropriate taxonomic keys65,66.

Data were collected in 2021 and 2022, with selected images being extracted from the raw video footage, and divided into three subsets. All training images were collected in 2021, while the final validation images were collected in 2022, ensuring complete spatiotemporal and biological novelty. Images yielded a maximum simultaneous co-occurrence of six V. velutina, this being observed in Jersey; and five V. crabro, this being recorded in the UK. As a processing step prior to training, images were letterboxedthis being the process of downsampling to 640640 for enhanced throughput performance, while maintaining a 16:9 aspect ratio and filling any residual image space with blank pixels. This then allowed for extensive image augmentation during training, producing three additional variations to supplement each original frame, and thus increasing the total number of images by a factor of four. The specific details of each training data subset are outlined in the following sections.

A collection of 1717 images for training and 430 for initial validation metrics, totalling 8,588 after augmentation. This set contained hornet images with a 50:50 split between V. velutina and V. crabro, while the number of non-target insects was intentionally limited. Data were collected from bait stations at sites in the UK and Portugal.

A collection of 2196 images for training and 549 for initial validation metrics, totalling 10,980 after augmentation. This set contained all hornet images from the HTS, in addition to 598 images of non-target insects. Images of non-target insects included a representative selection of species attracted to the bait station, with a focus on visually similar genera such as Vespula, Dolichovespula, and Polistes. All insects were identified to the genus level, utilising a combination of expert assessment and the relevant taxonomic identification resources65,67. A full list of non-target taxa is provided in (TableS1). These data were collected from bait stations at sites in the UK, Jersey, and Portugal.

A collection of 557 images for final validation only, totalling 2228 after augmentation. Of these, 433 contained instances of V. velutina and V. crabro in a 50:50 split, including multiple co-occurrences of both species and non-target insects. The remaining images contained a combination of non-target species and empty bait stations under different lighting and climatic conditions. Validation data were collected from bait stations at sites in the UK, Jersey, France, and Portugal.

Annotation was performed using the Plainsight AI (Plainsight) software interface. This allowed for expedited labelling via automated polygon selection and AI-assisted predictive annotation. Two classes of annotation were generated, corresponding to V. velutina and V. crabro, and these were then manually applied to a random selection of training frames. Polygonal masks included hornet bodies and wings, and excluded legs and antennaeas we found these to be redundant during testing. Once ~500 frames had been annotated manually, we then used this data to train an automated detection and segmentation model within the labelling interface, allowing us to more rapidly generate further annotations for training. Prior to data export, all annotations were reviewed manually, and corrections made where required. Annotations were exported in COCO format, enabling full segmentation of hornet features from the background68.

To develop a hardware-specific hornet detection and classification model, we combined our extensive image dataset with bespoke augmentations to obtain high predictive confidence. The VespAI detection algorithm is built on the YOLOv5 family of machine vision models, specifically YOLOv5sa variant optimised to run on portable processors such as the Raspberry Pi 448. As a front-end pre-filter to this, we incorporated the lightweight ViBe50 background subtraction algorithm, allowing the system to remain passive in the absence of motion (Fig.2a). Specifically, this pre-filter detects motion from the raw video input, extracts the contours of moving insects, and retains only objects within a reference size range generated from known hornet detections (Fig.2a and S1). Consequently, energy is conserved, as only relevant candidate frames are passed on to the YOLOv5 detection algorithm itself. This then applies a single fully convolutional neural network (F-CNN) to images (Fig.2b), providing superior speed, accuracy, and contextual awareness when compared to traditional regional convolutional neural networks (R-CNN)49,69.

All models were built and optimised using the PyTorch70 machine learning environment, with the aim of generating an end-to-end software package that would run on a Raspberry Pi 4. This was achieved by testing models on a range of YOLOv5 architectures, specifically YOLOv5m, YOLOv5s, and YOLOv5n; thus optimising them to include the minimum number of parametersthis being ~7 millionwhilst maintaining their performance (Fig. S2b).

Final models were trained and tested utilising a NVIDIA Tesla V100 Tensor Core GPU (NVIDIA), with a total of 200300 epochs per model, and a batch size of nine images. Model optimisation was evaluated via three loss functions; bounding box loss, this being the difference between the predicted and manually annotated bounding boxes; objectness loss, defined as the probability that bounding boxes contained target images; and cross-entropy classification loss, encompassing the probability that image classes were correctly classified (Fig. S2). In all cases, training concluded when there was no improvement in these three loss functions for a period of 50 epochs.

The prototype system was developed to provide proof-of-concept for remote detection under field-realistic conditions. The VespAI software was installed on a Raspberry Pi 4, running an Ubuntu desktop 22.04.1 LTS 64-bit operating system. This was then connected via USB to a variety of 1080p cameras, and tested using both mains and battery power supplies. These components were mounted on top of a bait station in the standard camera position, and a remote device was connected to the Pi server via the secure shell command. This allowed the hardware to be controlled remotely, and hornet detections viewed from a corresponding computer.

The setup was validated in Jersey during 2023, testing five candidate camera models and four prototype systems over a total of 55 trials at two field sites, yielding >5500 frames for analysis. Cameras were selected to test system robustness to differing lens and sensor options, while maintaining a standard resolution of 1080p across a range of cost-effective models (Fig. S5 and TableS2). Prior to testing, each camera was calibrated to a specific height, thus ensuring that the relative size of objects in frame remained constant across differences in lens angle and focal length (TableS2). Field sites were situated in Jersey to allow visits from both V. velutina, and V. crabro workers, along with a variety of common non-target insects, thus providing a rigorous test of the system under representative conditions.

Each trial consisted of a100-frame test, with the monitor capturing and analysing frames in real-time at intervals of either 5 or 30sthese being based on known hornet visitation durations (Fig. S4). Specifically, in the first 38 trials, the system was set to collect images at 5s intervals; before optimising to 30s intervals in the final 17 trials (TableS3), thus allowing for maximum power and data storage conservation, in tandem with reliable hornet detection. (Fig. S4). Results were then manually validated, and compared to the corresponding model predictions to calculate evaluation metrics.

Following field testing, the system was configured to integrate a DS3231 Real-Time Clock module, thus ensuring accurate timestamps for detections in the absence of external calibration.

To train the detection models and enable customised image augmentation, we employed the Python packages PyTorch, Torchvision, and Albumentations. Models were then evaluated via k-fold cross-validation, specifically utilising the metrics of precision, recall, box loss, objectness loss, classification loss, mean average precision (mAP), and F1 score (Fig. S2 and Table1). Cross-validation analyses employed a subsample (k) of 5, as this proved sufficient to select an optimised detection classifier that balanced model size with performance. Resultant model rankings were based on mean cross-validation scores, calculated using the Python packages scikit-learn and PaddlePaddle, and the YOLOv5 integrated validation functionality. Additional performance visualisations were generated via the packages Seaborn, Matplotlib, and NumPy. All statistical analyses were performed in SPSS (release v. 28.0.1.1) and Python (release v. 3.9.12).

Cross-validation of polygonal and box annotation techniques utilised precision, recall, box loss, objectness loss, classification loss, and mAP as response variables, and compared models with copy-paste augmentation levels of 0%, 30%, and 90%, with the former of these corresponding to box annotations.

Visualisation of training data subsets to ensure sufficient image novelty utilised frequency distribution analyses of blur, area, brightness, colour, and object density between the HTS, H/NTS, and VS.

Cross-validation of model architectures employed precision, recall, box loss, objectness loss, classification loss, and mAP as response variables, and compared models using the YOLOv5m, YOLOv5s, and YOLOv5n architectures.

Cross-validation of models trained on the hornet training subset and hornet/non-target training subset used F1 score and mAP as response variables, and compared models trained on the HTS and H/NTS, validated against the VS.

The LRP class classification model employed normalised contributions to classification decisions as a response variable, and compared same and opposite class pixel contributions. The LRP training subset classification model used normalised contributions to classification decisions as a response variable, and compared models trained on the HTS and N/HTS.

Precision and recall analyses were utilised to compare camera models, with comparisons based on median performance across test types for each metric.

Model development utilised a sample of 3302 images collected from a total of four countries, each consisting of multiple sampling sites. Data augmentation further expanded this sample to 13,208 images and provided additional variation to enhance model robustness. Analyses of the prototype system employed a sample of >5500 frames, collected across 55 field trials at two sites in Jersey. The source data underlying all figures and analyses are available within the supplementary data. Full details of statistical tests, subset sample sizes, and model selection procedures are provided in the results and statistical analyses sections.

Further information on research design is available in theNature Portfolio Reporting Summary linked to this article.

Originally posted here:

VespAI: a deep learning-based system for the detection of invasive hornets | Communications Biology - Nature.com